Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07560579
Active, not recruiting Not applicable

Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity

NCT07560579 · tracked via the Priya Life Science USA tracker
Sponsor
Million Marker Wellness, Inc
Phase
Not applicable
Started
2025-08-18
Last updated
2026-10-06

Condition(s) studied

Obesity &Amp;Amp;Amp; OverweightEnvironmental ExposureOverweight (BMI > 25)

Investigational drug(s) / intervention(s)

Educational curriculumWeight loss ApplicationUrinary EDC metabolite testingSiphox clinic biomarker testWeight loss reporting

Educational curriculum: A self-directed online interactive curriculum of EDC material, with access to live coaches and an online forum.

Weight loss Application: A paid, self-directed weight loss application.

Urinary EDC metabolite testing: Mail-in urine samples tested for metabolites of bisphenols, phthalates, parabens, and oxybenzone.

Siphox clinic biomarker test: Mail-in blood samples tested for clinical biomarkers.

Weight loss reporting: Self-reported weight loss.

Study summary

The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial. The main questions this study aims to answer are:

1. If MM's 12-week EDC intervention program (EDC testing and report-back, EDC reduction curriculum) can reduce weight?
2. If a 12-week validated digital weight loss program can reduce EDC exposures?
3. What is the effectiveness of the two interventions at reducing weight and urinary EDC metabolites? Participants will be assigned to one of these two arms. Participants will collect their urine and blood samples pre- and post-intervention, and will take a comprehensive exposure survey before sending back their samples. This exposure survey will ask about participant's weight loss literacy, environmental health literacy, product use, diet, and lifestyle behaviors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * BMI over 25 * Not pregnant or breast feeding * Do not have diabetes, kidney disease, liver disease, cardiac disease, pulmonary disease or cancer. * Do not smoke * Not in another weight loss program or on GLP-1 * Have access to a smartphone or computer Exclusion Criteria: * BMI under 25 * Pregnant or breast feeding * Have diabetes, kidney disease, liver disease, cardiac disease, pulmonary disease or cancer. * Smoke * In another weight loss program or on GLP-1 * Do not have access to a smartphone or computer

Primary outcome measure(s)

  • Changes in weight after intervention. — Pre and post intervention (4 months between measurements)
    EDC intervention that reduces EDC exposure also help individuals to lose weight. Comparing the two interventions to see which is more effective (EDC intervention or traditional weight loss intervention).
  • Changes in Endocrine Disrupting Chemical - Environmental Health Literacy (EDC-EHL) after the intervention. — Measured before the intervention, after the intervention (4 months after baseline), and at follow-up (1 months after the intervention)
    This surveys assesses EDC-specific environmental health literacy, based on questions in a 5-point Likert scale from 1 (strongly agree) to 5 (strongly disagree) or 1 (never) to 5 (always). Responses will be reverse coded during analysis as needed so that higher numbers reflect positive outcomes (higher EDC-EHL).
  • Changes in EDC metabolites after the intervention — Pre and post intervention (4 months in between measurements)
    Urinary EDC metabolites include bisphenols, phthalates, parabens and oxybenzone

Trial sites (1)

FacilityCityRegionStatus
Million Marker Berkeley California

More Million Marker Wellness, Inc. trials in the USA

Sperm, Exposure and Endocrine Disruptors Starting soon

Other trials for the same condition

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters Recruiting
A Study to Assess the Efficacy of Public Health Campaigns in Reducing Lead Exposure Starting soon
A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07560579 on ClinicalTrials.gov ↗ ← All trials in the USA